[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[Apogee Therapeutics, Inc. Common Stock](/topic/$apge)

### Sentiment: XX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$apge/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$apge/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Week**: XXX% no change  
**1 Month**: XX% +3%  
**6 Months**: XX% -XX%  
**1 Year**: XX% -X%  
**1-Year High**: XXX% on 2024-10-21  
**1-Year Low**: X% on 2025-01-28  

**Most Supportive Themes**
- **Positive Analyst Ratings and Price Targets:** (35%) Several analysts have reiterated 'Buy' ratings and provided positive price targets for APGE, contributing to positive sentiment.
- **Closing of Public Offering:** (25%) The announcement of the closing of a public offering and the exercise of the underwriters' option to purchase additional shares has been met with positive reactions.
- **Potential Dupixent Rivalry:** (20%) TD Cowen highlighted APGE's eczema drugs as potential rivals to Dupixent, which has generated significant interest.
  
**Most Critical Themes**
- **Public Offering Concerns:** (10%)  The public offering, while closed, initially caused a price drop, indicating some investor concern.
- **After-Hours Price Drop:** (10%)  The stock experienced a price decrease after the announcement of the public offering, which may be a concern for some investors.
  
Network engagement breakdown:  
| Network | Positive | %   | Neutral | %  | Negative | %  |
| ------- | -------- | -   | ------- | -  | -------- | -  |
| X       | XXXXX    | XX% | XXX     | X% | XX       | X% |
|         |          |     |         |    |          |    |
| Total   | XXXXX    | XX% | XXX     | X% | XX       | X% |